NCT00388076View on ClinicalTrials.gov

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 28, 2006

Primary Completion Date

July 21, 2009

Study Completion Date

July 21, 2009

Conditions
Neoplasms, Breast
Interventions
DRUG

Pazopanib

pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3

DRUG

Lapatinib

Lapatinib in combination with pazopanib and paclitaxel in Part 3

DRUG

paclitaxel

in combination with pazopanib

DRUG

carboplatin

in combination with pazopanib

Trial Locations (3)

37203

GSK Investigational Site, Nashville

44106

GSK Investigational Site, Cleveland

08901

GSK Investigational Site, New Brunswick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00388076 - Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | Biotech Hunter | Biotech Hunter